Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. ACN
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. NVDA

Go back to Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis
Regeneron (NASDAQ: REGN) Delayed: 808.59 -19.13 (2.31%)
Previous Close $827.72    52 Week High $592.36 
Open $814.36    52 Week Low $325.35 
Day High $821.17    P/E 212.23 
Day Low $799.42    EPS $3.81 
Volume 212,430